Anticoagulation is a cornerstone of management in cardiovascular disease. Within the last decade, several new anticoagulation strategies have been introduced and trialed in the management of acute coronary syndrome, percutaneous coronary intervention, atrial fibrillation, cardioversion, and cardiac valve replacement. As data to support novel anticoagulant use emerges, it is imperative that treating physicians remain up to date on optimal anticoagulation strategies in cardiovascular disease. In this review, we provide a concise summary of the data supporting existing anticoagulation strategies, and emphasize strengths and limitations of novel anticoagulant use in these settings.
| INTRODUC TI ON
Anticoagulation is a cornerstone of management in cardiovascular disease. Within the last decade, several new anticoagulation strategies have been introduced and trialed in the management of acute coronary syndrome, percutaneous coronary intervention, atrial fibrillation, cardioversion, and cardiac valve replacement. As data to support novel anticoagulant use emerges, it is imperative that treating physicians remain up to date on optimal anticoagulation strategies in cardiovascular disease. In this review, we provide a concise summary of the data supporting existing anticoagulation strategies, and emphasize strengths and limitations of novel anticoagulant use in these settings.
| ANTICOAG UL ATI ON IN ACUTE CORONARY SYNDROME

| Non-ST elevation acute coronary syndrome
Non-ST elevation acute coronary syndrome (NSTE-ACS) encompasses both non-ST elevation myocardial infarction (NSTEMI) and unstable angina (UA). 1 Antiplatelet and anticoagulant therapies are mainstays of treatment for these conditions in order to slow or stabilize thrombus growth and reduce myocardial damage. The following section outlines guidelines for anticoagulation in NSTE-ACS and data comparing the efficacy of unfractionated, low molecular weight, and ultra-low-molecular-weight heparins in this setting.
| Current recommendations for anticoagulation in NSTE-ACS
The 2014 American Heart Association (AHA)/American College of Cardiology (ACC) guidelines describe several alternatives for anticoagulant therapy in patients presenting with NSTE-ACS, in addition to antiplatelet therapy:
• Enoxaparin, 30 mg loading dose followed by 1 mg/kg every 12 hours,
• Unfractionated heparin, 60 IU/kg loading dose (max 4000 IU) followed by 12 IU/kg/h (max 1000 IU/h)
• Fondaparinux, 2.5 mg daily, or
• Bivalirudin, 0.10 mg/kg loading dose followed by 0.25 mg/kg/h (early invasive strategy only). 2 The choice of anticoagulant therapy should be made in conjunction with the overall management strategy of the patient. Intravenous anticoagulants with a shorter half-life, such as UFH or bivalirudin, may be favored in patients being managed with an early invasive strategy,
given their theoretical advantages in the setting of possible mechanical complications in the cardiac catheterization laboratory. The anticoagulant effects of heparin products may also be reversed with the use of protamine sulfate, making them an option for patients at high risk of bleeding; however, the small risk of allergic reactions with protamine must be taken into consideration. 3 European Society of Cardiology (ESC) guidelines express a preference for fondaparinux due to its association with decreased major bleeding, but concerns about increased risk for catheter-related thrombosis during PCI have likely limited its widespread use. Patients receiving fondaparinux who undergo angiography also must receive additional anticoagulation with an anti-IIa agent (either UFH or bivalirudin). Nevertheless, fondaparinux may be preferable to other agents, especially for those patients not undergoing angiography.
| Antiplatelet alone vs antiplatelet and anticoagulant
A mortality benefit from either unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in addition to antiplatelet therapy (primarily aspirin, ASA) has been found by some, but not all, clinical trials. Meta-analysis of six trials comparing UFH and ASA to ASA alone showed a relative risk reduction of 0.67, which approached statistical significance (CI 95% 0.44-1.02; P = 0.06) in death and non-fatal MI in patients receiving both UFH and ASA when compared to ASA alone. 4 A small study comparing LMWH and ASA to ASA alone suggested significantly less recurrent angina, non-fatal MI, and urgent revascularization in patients receiving LMWH and ASA. 5 A larger RCT comparing LMWH (dalteparin) and ASA to ASA alone showed a significant reduction in death or MI in patients treated with LMWH and ASA (1.7% and 4.7%, respectively, CI 0.20-0.68; P = 0.001). This 3% absolute risk reduction (65% relative risk reduction) was not sustained after 40 days. 6 Interestingly, concurrent ASA dosing used in these trials is variable;
ranging from 75 to 650 mg loading or daily dose; this may affect relative efficacy of UFH or LMWH and ASA treatment groups when compared to ASA alone.
| Antiplatelet and unfractionated heparin vs antiplatelet and low-molecular-weight heparin
Both UFH and LMWH products are used clinically to manage un- 
| Low-molecular-weight heparin vs ultra-lowmolecular-weight heparin
Fondaparinux is a parenteral synthetic pentasaccharide and highly selective indirect factor Xa inhibitor. OASIS-5, a double-blind multicenter trial which compared fondaparinux and enoxaparin in patients with NSTE-ACS, found no difference in death, myocardial infarction, or refractory ischemia after 9 days (HR 1.01; 95% CI 0.90-1.13, P = 0.007 for non-inferiority). Furthermore, the study reported a A summary of modern trials in NSTE-ACS is listed in Table 1, and an overview of anticoagulation use in NSTE-ACS is outlined in 
| Summary statements
• Major guidelines recommend anticoagulation with a heparin product or bivalirudin for all patients with NSTE-ACS.
• A mortality benefit from either UFH or LMWH in addition to antiplatelet therapy has been found in some, but not all, clinical trials.
• There is less procedural bleeding with UFH in patients undergoing early intervention.
• Some studies suggest fondaparinux has the best safety profile in patients not undergoing immediate percutaneous intervention.
| ANTI COAG UL ATI ON IN PATIENTS WITH RECENT PERCUTANEOUS CORONARY INTERVENTI ON
Percutaneous coronary intervention (PCI) mandates the use of dual antiplatelet therapy (DAPT) for a period of time, leading to significant bleeding risks in the estimated 5%-10% of patients who require concurrent systemic anticoagulation. 16 This population is heterogeneous and includes patients with mechanical heart valves, atrial arrhythmias, and a history of venous thromboembolism, who may receive either balloon angioplasty, bare-metal stents, or drug-eluting stents. Bleeding risks, tolerance for withholding anticoagulation, and the minimum duration of medical therapy varies dramatically between patients, making individualized interpretation of the evidence-base imperative to safe and effective treatment.
| Current recommendations for anticoagulation after percutaneous coronary intervention (PCI)
For patients who undergo PCI for ACS, current AHA/ACC guidelines, a 2016 focused update, and the current ESC guidelines recommend 12 months of DAPT in patients without significant bleeding risks (Class 1). 17 Both guidelines suggest that the dura- who undergo PCI for stable ischemic heart disease (SIHD) may discontinue DAPT at 6 months, although a longer duration may be considered in patients who tolerate DAPT well. 19 There is no clear consensus regarding appropriate management of patients with concurrently indicated DAPT and full dose anticoagulation;
the ESC now recommends consideration of one to six months of triple therapy followed by dual therapy or dual therapy only (Class IIa-b). 17 The ESC recommends against the use of ticagrelor or prasugrel, in favor of clopidogrel, and consideration of PPI given this combination has the best evidence. 17 There is a paucity of data comparing the efficacy and safety of triple therapy to dual therapy for patients who receive coronary stents.
Recently, however, three prospective trials have compared the two regimens ( Table 2 20 Approximately 65% of patients in both arms received drug-eluting stents. While the study was not powered to detect efficacy in terms of preventing stent thrombosis or stroke, there were no significant differences in the incidence of either between the two groups. There was a detectable mortality benefit in favor of dual therapy. 20 More recently, two prospective trials compared the use direct oral anticoagulants (DOACs) as part of dual vs triple-therapy regimens. The PIONEER trial compared low-dose rivaroxaban (15 mg once daily) plus a P2Y12 inhibitor for 12 months (group 1), very-low-dose rivaroxaban (2.5 mg twice daily) plus DAPT for 1, 6, or 12 months (group 2), or standard therapy with a dose-adjusted VKA (once daily) plus DAPT for 1, 6, or 12 months (group 3). 21 The primary endpoint was clinically significant bleeding. Group 1 had significantly less bleeding than group 3 (16.8% vs 26.7%; P < 0.001).
Finally, the RE-DUAL PCI trial compared triple therapy with warfarin plus a P2Y12 inhibitor (clopidogrel or ticagrelor) and aspirin to dual therapy with dabigatran (110 or 150 mg twice daily) plus a P2Y12
inhibitor (clopidogrel or ticagrelor) and no aspirin. 22 Outside the United States, elderly patients (≥80 years of age; ≥70 years of age in Japan) were randomly assigned to the 110-mg dual-therapy group or the triple-therapy group. The primary endpoint was clinically relevant bleeding. The trial also evaluated non-inferiority of dual therapy with dabigatran (both doses combined) to triple therapy with warfarin with respect to incidence of a composite efficacy endpoint of thromboembolic events (myocardial infarction, stroke, or systemic embolism), death, or unplanned revascularization. The incidence of the primary endpoint was 15.4% in the 110-mg dual-therapy group and 26.9% in the triple-therapy group (HR 0.52; 95% CI 0.42-0.63; P < 0.001 for non-inferiority; P < 0.001 for superiority) and 20.2%
in the 150-mg dual-therapy group compared with 25.7% in the corresponding triple-therapy group. (HR 0.72; 95% CI 0.58-0.88; P < 0.001 for non-inferiority). The incidence of the composite efficacy endpoint was 13.7% in the two dual-therapy groups combined as compared to 13.4% in the triple-therapy group (HR 1.04; 95% CI 0.84-1.29; P = 0.005 for non-inferiority). 22 Lastly, the AUGUSTUS trial is currently underway evaluating the use of dual therapy with apixaban vs triple therapy with warfarin. 23 Decisions in this space require a careful assessment of the risk of recurrent cardiovascular events and bleeding risk. It is important to be conscious of the significant risk of major bleeding with triple therapy with warfarin in all three trials, and the current data suggesting dual therapy with a DOAC is non-inferior.
| Summary
• 5%-10% of patients who undergo PCI will require concurrent systemic anticoagulation.
• Major guidelines suggest consideration of a patient's bleeding and thrombotic risk in determining the appropriateness of double vs triple therapy post-PCI.
• Trials comparing double vs triple therapy show significantly more bleeding with triple therapy, without an increase in thrombotic events in the dual therapy arm, although two of three studies
were not powered for efficacy. One study showed dual therapy to be non-inferior to triple therapy.
| ANTICOAG UL ATI ON IN NON -VALV UL AR ATRIAL FIBRILL ATION
| Epidemiology and risk stratification
Atrial fibrillation (AF) confers significant, age-dependent risk of ischemic stroke and subsequent associated morbidity and mortality. 24 Anticoagulant and antiplatelet agents have been found to reduce risk of ischemic events at variable rates; absolute values are dependent on both types of anticoagulant/antiplatelet and thrombotic risk in each individual patient. Risk in patients with non-valvular AF can be quantified by a CHA2DS2-VASc score, which synthesizes markers of cardiac function, cardiac risk, and patient age into a static score and associated percent risk reduction in stroke over 1 year.
Anticoagulation is recommended if CHA2DS2-VASc ≥ 2, though decision to anticoagulate must always be balanced by bleeding risk.
HAS-BLED, ATRIA, and HEMORR2HAGES can be used to quantify this risk. 24 These scores have limitations, however, as neither were developed in the DOAC era, nor are they designed to predict intracranial or fatal bleeding. It is tantamount to weigh the values and preferences of the patient when making decisions around indefinite anticoagulation.
| Current recommendations for anticoagulation in non-valvular atrial fibrillation
In patients with non-valvular AF and CHA2DS2-VASc ≥ 2, the ACC/ AHA guidelines recommend anticoagulation with a vitamin K agonist (VKA, warfarin, INR 2.0-3.0), dabigatran, rivaroxaban, or apixaban. 25 No anticoagulant is recommended for CHA2DS2-VASc = 0, and risk vs benefit discussion should be held for patients with atrial fibrillation and CHA2DS2-VASc = 1. 26 Cost, access to regular monitoring, 
TA B L E 2 Outcomes of trials comparing triple vs double therapy post-PCI
| Aspirin and clopidogrel
DAPT should not be preferentially used for stroke prevention in patients with AF. While the combination of ASA and clopidogrel was found to decrease the incidence of stroke in patients with AF compared to ASA alone in the ACTIVE-A trial, the combination resulted in a significantly increased rate of major bleeding (2.0% vs 1.3% per year, RR 1.57, 95% CI 1.29-1.92). 34 The ACTIVE-W trial comparing DAPT with ASA and clopidogrel to warfarin was stopped early because warfarin significantly lowered the annual rate of the primary endpoint compared to DAPT. 35 Overall, this suggests that DAPT is inferior to therapeutic anticoagulation and results in significantly more bleeding than ASA alone.
| Warfarin
Warfarin demonstrates decreased risk of stroke when compared to placebo or no treatment, ASA alone, or dual antiplatelet regimens in atrial fibrillation.
When compared to placebo or no treatment, warfarin is associated with a clinically and statistically significant reduction in combined ischemic and hemorrhagic stroke (RRR 65%; 95% CI 49%-74%) per year. 36 This yields an aggregate absolute risk reduction in combined ischemic and hemorrhagic stroke of 2.7% when used for primary prevention, and 8.4% when used for secondary prevention. 28 When compared to ASA alone, warfarin is associated with a reduction in composite hemorrhagic and ischemic stroke (RRR 38%; 95% CI 18-52); interestingly, this is primarily driven by risk reduction in secondary prevention (0.7% ARR per year for primary prevention; 7.0% ARR per year for secondary prevention). 24 In an effort to reduce burden associated with long-term 
| Direct thrombin inhibitors
Antiplatelet strategies are consistently shown to be inferior to VKAs in the prevention of stroke in patients with atrial fibrillation, however, direct thrombin inhibitors offer an alternative to ASA and VKA with less inter-patient variability and decreased monitoring burden.
The RE-LY trial, a randomized trial comparing dabigatran to warfarin in patients with atrial fibrillation, suggested that patients treated with 150 mg dabigatran twice daily when compared to warfarin had a statistically significant decreased risk of stroke or systemic embolism (RR 0.66; 95% CI 0.53-0.82; P < 0.001). 37 Though rates of major bleeding between these two treatment regimens were similar, dabigatran, 150 mg twice daily, was associated with a significant increase in major gastrointestinal bleeding when compared to warfarin. Notably, dabigatran, 110 mg twice daily, was non-inferior to warfarin, and demonstrated less risk of major bleeding.
| Factor Xa inhibitors
When compared to ASA, the AVERROES trial suggested that apixaban confers reduced risk of stroke or systemic embolism in patients with non-valvular atrial fibrillation, without concurrently increased bleeding risk. 38 Furthermore, when compared to warfa- CI 0.96-1.34, P = 0.10 compared to warfarin). Annualized rate of major bleeding was 3.43% for patients using warfarin, 2.75% for patients using high-dose edoxaban (HR 0.80; 95% CI 0.71-0.91, P < 0.001 compared to warfarin), and 1.61% for patients taking low-dose edoxaban (HR 0.47; 95% CI 0.41-0.55, P < 0.001 compared to warfarin). 39 Similarly, ROCKET-AF, a randomized controlled trial comparing warfarin to rivaroxaban, showed net clinical benefit favoring rivaroxaban, which was likely driven by decreased rates of ischemic events and major or fatal organ bleeding. Notably, these studies exclude patients with significantly impaired renal function, recent major bleeding events, and valvular atrial fibrillation. 40 An overview of anticoagulation use in atrial fibrillation is outlined in Figure 2 .
| Summary statements
• Systemic anticoagulation is recommended for non-valvular atrial fibrillation with CHA 2 DS 2 -VASc ≥2, and should be considered for CHA 2 DS 2 -VASc ≥1; however, there are limited trial data to support this practice.
• Aspirin as monotherapy is inferior to VKA or DOAC for stroke prevention in atrial fibrillation, and studies suggest that efficacy for stroke prevention decreases with increasing age, while bleeding risk persists.
• Concurrent aspirin and clopidogrel do not decrease stroke risk in patients with atrial fibrillation and are inferior to VKA for stroke prevention.
• DOACs are superior or non-inferior to VKAs in decreasing risk of stroke or systemic embolism in atrial fibrillation, and have equivalent or decreased bleeding risk.
• DOACs have not been extensively validated in patients with severe renal disease or valvular atrial fibrillation.
| ANTI COAG UL ATI ON IN C ARDIOVER S ION FOR ATRIAL ARRHY THMIA S
Anticoagulation is necessary to minimize the risk of acute thromboembolism after cardioversion for atrial arrhythmias. 41 While the overall rate of thromboembolic complications is low in the modern era if appropriate anticoagulation is used, patients who are not anticoagulated carry a significantly increased risk. [41] [42] [43] Current guidelines risk-stratify based on the time in atrial arrhythmia. 26 (CHADS-VASc >1), guidelines are quick to point out that this practice has not been evaluated in clinical trials. 26 Large observational data have confirmed that stroke rate is low (0.7%) when cardioversion was performed without anticoagulation within 48 hours of AF onset. 44 Transesophageal echocardiography may be used to guide cardioversion in patients with atrial fibrillation who desire early cardioversion. 45 While warfarin has been used for decades to anticoagulate patients undergoing cardioversion, 46 DOACs have recently been evaluated as an alternative method of anticoagulation in this setting. The ENSURE-AF trial compared edoxaban to warfarin for stroke prevention in 2199 patients undergoing electrical cardioversion. 47 The primary efficacy endpoint occurred in five (<1%) Stroke and systemic embolism rates at 30 days were 0.8%, 0.3%, and 0.6% (dabigatran, 110 mg vs warfarin, P = 0.71; dabigatran, 150 mg vs warfarin, P = 0.40); these rates were similar in patients with and without TEE. Major bleeding rates were 1.7%, 0.6%, and 0.6% (dabigatran, 110 mg vs warfarin, P = 0.06; dabigatran, 150 mg vs warfarin, P = 0.99). Lastly, a systematic review evaluating the subsets of patients who underwent cardioversion in major DOAC atrial fibrillation trials reported outcomes similar or improved as compared to warfarin. 50 Direct oral anticoagulants appear to be a safe and effective alternative to warfarin for anticoagulation in cardioversion; some studies suggest improved outcomes with DOAC use. 51 Guidelines that recommend warfarin over DOACs were published prior to the majority of the former data being published. 25 It is reasonable to use DOACs both peri-and postprocedurally in patients undergoing cardioversion.
| Summary statements
• Patients in atrial fibrillation for less than 48 hours may undergo immediate cardioversion. Most guidelines recommend anticoagulation for a minimum of 4 weeks after cardioversion (and consideration of indefinite anticoagulation in patients at risk of stroke).
• Patients in atrial fibrillation for greater than 48 hours should receive therapeutic anticoagulation for 3 weeks prior to cardioversion and for a minimum of 4 weeks after cardioversion (and consideration of indefinite anticoagulation in patients at risk of stroke). Patients not willing to wait 3 weeks may undergo a screening transesophageal echocardiogram (TEE) to guide early cardioversion.
• Multiple trials suggest that DOACs are effective and safe for anticoagulation in patients undergoing cardioversion.
| ANTICOAG UL ATION FOR ARTIFICIAL VALVE S
Patients with implanted mechanical or bioprosthetic valves are at increased risk of thromboembolic events. Mitral valve replacements carry higher risk, likely due to flow dynamics across the valve and often associated left atrial enlargement or atrial fibrillation. 52 
| Modifiable risk factors
All patients receiving a prosthetic valve should be counseled regarding modifiable risk factors for thromboembolic events. In patients undergoing aortic valve replacement, postoperative infection (HR 2.0), hypertension (HR 2.0), and diabetes (HR 1.9) are associated with additional risk of postsurgical thromboembolic event. 53 Additional pharmacologic antiplatelet and anticoagulant therapy varies by anatomic valve replaced, type of prosthesis, concurrent comorbidities, and bleeding risk.
| Bioprosthetic valves
The ACC and ESC recommendations for antiplatelet and anticoagulant therapy in patients receiving a bioprosthetic valve vary primarily based on anatomic valve replaced and method of replacement. In patients with surgical tricuspid or mitral valve replacement, a VKA is recommended for three months after surgical implantation. In patients with surgical aortic valve replacement, low-dose ASA (70-100 mg daily) is recommended for three months after implantation. In patients receiving transcatheter aortic valve replacement, dual antiplatelet therapy is recommended for 3-6 months after intervention, followed by lifelong single antiplatelet therapy. 54 A retrospective cohort analysis which measured rates of death, On-X mechanical valve in the aortic position, a lower INR target of 1.5-2.0 plus ASA 81 mg/day can now be considered (after 3 months of standard-dose warfarin), given the results of PROACT. 60 
| Direct oral anticoagulants
Direct oral anticoagulants are currently contraindicated as agents to prevent thromboembolic phenomena in patients with prosthetic valves.
The RE-ALIGN trial, a multicenter RCT which compared VKA to dabigatran for postvalvular prosthesis anticoagulation, was discontinued after 12 weeks due to increased rates of both composite adverse outcome (stroke, transient ischemic attack, systemic embolism, myocardial infarction, or death) and bleeding events in the dabigatran group. 61 While clinical trials are underway for other DOACs, 62 they are contraindicated in patients with mechanical heart valves.
An overview of anticoagulation use in mechanical valves is outlined in Figure 3 .
| Summary statements
• Patients with mechanical heart valves require indefinite therapy with a vitamin K antagonist (DOACs are contraindicated in this space). Aspirin should be given concurrently in patients at low bleeding risk.
• Patients with bioprosthetic valves may require a short course of anticoagulation and/or varying periods of antiplatelet therapy depending on the type and location of valve used.
F I G U R E 3 Anticoagulation use in mechanical heart valves [Colour figure can be viewed at wileyonlinelibrary.com]
| S ECONDARY PROPHYL A XIS IN C ARDIOVA SCUL AR DIS E A S E
All major guidelines recommend the use of antiplatelet agents for secondary prevention of cardiovascular events. 63, 64 There is a plethora of data to suggest that oral anticoagulation, alone or in combination with aspirin, is superior at secondary prevention to aspirin alone, but results in significantly increased rates of bleeding precluding its routine use. 65 In the modern era, a single trial, COMPASS, assesses the use of low-dose anticoagulation with rivaroxaban for the secondary prevention of cardiovascular events. 66 The 
| Summary statements
• Low-dose aspirin remains the recommended drug for secondary prevention of cardiac events.
• Rivaroxaban-plus-aspirin results in lower cardiac events, but a significantly increased rate of bleeding precluding its routine use. 
| OTHER IND I C ATI ON S FOR ANTI COAG UL ATI ON IN C ARD IAC PATIENTS
| STEMI (STE-ACS)
STEMI is a medical emergency requiring urgent evaluation by a cardiologist. STEMI may be managed through three main pathways:
Primary 74 An overview of anticoagulation use in STE-ACS is outlined in 
| Intra-cardiac thrombi
LV thrombus may occur after myocardial infarction, particularly in cases of large anterior STEMI in the distribution of the left anterior descending coronary artery. The incidence in the modern era of advanced reperfusion techniques is low, about 4% in two series. 81, 82 The major risk of LV thrombus in this setting is potential embolization before clot resolution occurs. Data are minimal on embolization risk, but in one series of 85 patients with LV thrombus event occurred in 11 (13 percent). 83 Data on appropriate anticoagulation therapy is limited, but a small series found that none of the 25 patients who received anticoagulation treatment had an embolic event. Embolization occurred in seven of 18 patients who had not received anticoagulation. 84 Current guidelines from the ACCP recommend 3 months of anticoagulation for patients with anterior MI complicated by LV thrombus or those at high risk for LV thrombus (ejection fraction <40%, anteroapical wall motion abnormality) in conjunction with appropriate antiplatelet agents. 85 The role of prophylactic anticoagulation following anterior myocardial infarction is unclear. 86 While some data suggest a benefit in preventing recurrent cardiovascular events, recent data have failed to find a decrease in the incidence of cardiovascular events, but did show a numerically increased rate of major bleeding. 87 Atrial thrombi most commonly involve the left atrial appendage and are most often associated with atrial arrhythmia. Treatment generally involves indefinite anticoagulation as is recommended for atrial fibrillation.
| Pulmonary hypertension
Pulmonary hypertension is a heterogeneous disease, but anticoagulation is mandated in patients with type 4 pulmonary hypertension (chronic thromboembolic pulmonary hypertension
[CTEPH]). Anticoagulation use is controversial in patients with type I pulmonary hypertension (idiopathic, heritable, or drug induced). A 2006 systemic review noted the discordance in the literature, describing five studies that found a survival benefit with anticoagulation while two did not. 88 The AHA 2009 Expert Consensus Document on Pulmonary Hypertension recommends warfarin anticoagulation with a goal international normalized ratio (INR) 1.5-2.5 in idiopathic PAH patients. 89 The 2015 ESC/ ERS guidelines also recommend anticoagulation with an INR goal of 2.0-3.0. 90 Both groups contend that there is a lack of strong data in this space.
| Left ventricular assist devices
Left ventricular assist devices (LVADs) are being increasingly used to bridge patients with end-stage heart failure to cardiac transplant or to palliate symptoms in patients who are not candidates for transplantation. 91 LVAD requires uninterrupted anticoagulation to prevent pump thrombosis, which can result in severe complications including device failure and embolic stroke. 91 This is balanced with a high rate of patient bleeding, particularly GI bleeding in part due to the development of acquired von Willebrand disease. 
